185 related articles for article (PubMed ID: 18337766)
1. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
McCubrey JA; Steelman LS; Abrams SL; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM
Leukemia; 2008 Apr; 22(4):708-22. PubMed ID: 18337766
[TBL] [Abstract][Full Text] [Related]
2. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
3. MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Jokinen E; Koivunen JP
Ther Adv Med Oncol; 2015 May; 7(3):170-80. PubMed ID: 26673580
[TBL] [Abstract][Full Text] [Related]
4. Cell Populations Expressing Stemness-Associated Markers in Vascular Anomalies.
Kilmister EJ; Hansen L; Davis PF; Hall SRR; Tan ST
Front Surg; 2020; 7():610758. PubMed ID: 33634164
[TBL] [Abstract][Full Text] [Related]
5. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.
Fransecky L; Mochmann LH; Baldus CD
Mol Cell Ther; 2015; 3():2. PubMed ID: 26056603
[TBL] [Abstract][Full Text] [Related]
6. Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.
Knight T; Irving JA
Front Oncol; 2014; 4():160. PubMed ID: 25009801
[TBL] [Abstract][Full Text] [Related]
7. Pathway-Directed Therapy in Multiple Myeloma.
John L; Krauth MT; Podar K; Raab MS
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916289
[TBL] [Abstract][Full Text] [Related]
8. Gigantol Targets Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K/AKT and JAK/STAT Pathways in Ectopic Lung Cancer Xenografts.
Losuwannarak N; Maiuthed A; Kitkumthorn N; Leelahavanichkul A; Roytrakul S; Chanvorachote P
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861050
[TBL] [Abstract][Full Text] [Related]
9. Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors.
Gupta A; Das D; Taneja R
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610991
[TBL] [Abstract][Full Text] [Related]
10. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
11. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
[TBL] [Abstract][Full Text] [Related]
12. Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.
Liao B; Wang J; Yuan Y; Luo H; Ouyang X
Cancer Cell Int; 2024 Mar; 24(1):122. PubMed ID: 38555465
[TBL] [Abstract][Full Text] [Related]
13. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
[TBL] [Abstract][Full Text] [Related]
14. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.
Zarrabi A; Perrin D; Kavoosi M; Sommer M; Sezen S; Mehrbod P; Bhushan B; Machaj F; Rosik J; Kawalec P; Afifi S; Bolandi SM; Koleini P; Taheri M; Madrakian T; Łos MJ; Lindsey B; Cakir N; Zarepour A; Hushmandi K; Fallah A; Koc B; Khosravi A; Ahmadi M; Logue S; Orive G; Pecic S; Gordon JW; Ghavami S
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958442
[TBL] [Abstract][Full Text] [Related]
15. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.
Li W; Li M; Huang Q; He X; Shen C; Hou X; Xue F; Deng Z; Luo Y
Front Chem; 2023; 11():1251986. PubMed ID: 37744063
[TBL] [Abstract][Full Text] [Related]
16. The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
Haghi A; Mohammadi Kian M; Salemi M; Eghdami MR; Nikbakht M
Int J Hematol Oncol Stem Cell Res; 2022 Oct; 16(4):250-263. PubMed ID: 36883106
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
Kaehler M; Cascorbi I
Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
[TBL] [Abstract][Full Text] [Related]
18. N-myc downstream regulated gene 1 inhibition of tumor progression in Caco2 cells.
He YX; Shen H; Ji YZ; Hua HR; Zhu Y; Zeng XF; Wang F; Wang KX
World J Gastrointest Oncol; 2022 Dec; 14(12):2313-2328. PubMed ID: 36568939
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.
Jamnongsong S; Kueanjinda P; Buraphat P; Sakornsakolpat P; Vaeteewoottacharn K; Okada S; Jirawatnotai S; Sampattavanich S
iScience; 2022 Oct; 25(10):105182. PubMed ID: 36248745
[TBL] [Abstract][Full Text] [Related]
20. A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy.
Ross BD; Jang Y; Welton A; Bonham CA; Palagama DSW; Heist K; Boppisetti J; Imaduwage KP; Robison T; King LR; Zhang EZ; Amirfazli C; Luker KE; Lee WY; Luker GD; Chenevert TL; Van Dort ME
Nat Commun; 2022 Aug; 13(1):4730. PubMed ID: 35977945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
